Sweden
TIGERQ AB, headquartered in Sweden, is a pioneering Cancer Genomics Software startup focused on developing highly precise sequencing analysis solutions. Established in 2018, the company is positioned to address the complex genetic changes responsible for 73% of all cancers, a currently under-addressed challenge within the €2.8B cancer genomic software market.
The startup operates at the intersection of Analytics and Biotechnology, offering patented technology that stands out for its accuracy and comprehensiveness. TIGERQ AB aims to capitalize on the growing demand for advanced genomic solutions, which could provide significant advantages in both clinical research and patient outcomes.
The company received a notable investment of €980.00K in a Seed Round on 17 March 2021, led by SmiLe Venture Hub. This financial backing indicates robust investor confidence and provides further resources to enhance their groundbreaking solutions, potentially leading to substantial advancements in cancer treatment methodologies.
